Original Research J Clin Psychiatry August 2022

Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial

JCP 2022;83(5):10.4088/JCP.21m14130

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2022;83(5):10.4088/JCP.21m14130 Clinical Summary Many young people with anxiety disorders remain significantly symptomatic despite cognitive-behavioral therapy and selective serotonin reuptake inhibitors, leaving clinicians with few next-step options. This trial addresses whether adjunctive cannabidiol can reduce anxiety in a treatment-resistant youth population while remaining tolerable enough for real-world use. FAQ Did cannabidiol reduce anxiety symptoms in young people with treatment-resistant anxiety disorders? 10 questions
Key Takeaways This was a highly treatment-experienced sample: the median duration of prior treatment as usual was 25.5 months, and among the 21 participants also taking antidepressants, the median duration was 19 months with a median number of 2 medication changes due to lack of efficacy or side effects. 6 takeaways Clinical Guide How should clinicians select and dose adjunctive cannabidiol for young people with treatment-resistant anxiety disorders? 7 steps Clinical Guide How should clinicians monitor safety and antidepressant interaction risk when using cannabidiol in young people with anxiety disorders? 7 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe